2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesisTreatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib
Kim R, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Reports 2018, 4: 443-445. PMID: 29984277, PMCID: PMC6031588, DOI: 10.1016/j.jdcr.2017.12.003.Peer-Reviewed Original Research
2017
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal Of The American Academy Of Dermatology 2017, 77: 675-682.e1. PMID: 28823882, PMCID: PMC6233876, DOI: 10.1016/j.jaad.2017.05.043.Peer-Reviewed Original ResearchConceptsTreatment of vitiligoJAK inhibitorsConsecutive patientsInhibitor tofacitinibJanus kinase inhibitor tofacitinibJAK inhibitor monotherapyRetrospective case seriesUltraviolet B phototherapyT-cell mediatorsBody surface areaJanus kinase inhibitorSeverity of diseaseB phototherapyInhibitor monotherapyCase seriesAutoimmune responseCell mediatorsAutoimmune diseasesCutaneous depigmentationLight exposureRetrospective natureStudy populationExisting therapiesControl groupTofacitinib
2016
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal Of Investigative Dermatology 2016, 137: 951-954. PMID: 27887955, PMCID: PMC5387413, DOI: 10.1016/j.jid.2016.10.044.Peer-Reviewed Original Research